Immunohistochemical expression of 14-3-3 σ protein in intraductal papillary-mucinous tumor and invasive ductal carcinoma of the pancreas

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 3105-3110

  Okada, Toshiyuki ^a   Masuda, Norihiro ^a   Fukai, Yasuyuki ^a   Shimura, Tatsuo ^a   Nishida, Yasuji ^b   Hosouchi, Yasuo ^c   Kashiwabara, Kenji ^c   Nakajima, Takashi ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^c GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

14 3 3 ; Carcinogenesis; Intraductal papillary mucinous tumor; Pancreatic carcinoma

Indexed keywords

KI 67 ANTIGEN; MUCIN 1; MUCIN 2; PROTEIN 14 3 3; PROTEIN P16; PROTEIN P53; TRANSCRIPTION FACTOR CDX2;

ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL STRUCTURE; CELL TYPE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA, MUCINOUS; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; EXONUCLEASES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746734236     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan, Tokyo: Foundation for Promotion of Cancer Research, 2005.
2. Solcia E, Capella C and Kloppel G: Atlas of Tumor Pathology. Tumors of the pancreas. Washington, DC: Armed Force Institute of Pathology, pp. 64-87, 1997.
3. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagino EF, Andren-Sandberg A and Damellot L: Pancreatitis and the risk of pancreatic cancer. The International Pancreatitis Study Group. New Engl J Med 328: 1433-1437, 1993.
4. Sommers SC, Murphy SA and Warren S: Pancreatic duct hyperplasia and cancer. Gastroenterology 27: 629-640, 1954.
5. Hruban RH, Wilentz RE and Kern SE: Genetic progression in the pancreatic ducts. Am J Pathol 156: 1821-1825, 2000.
6. 6 Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G, Longnecker DS, Luttges J and Offerhaus GJ: Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesion. Am J Surg Pathol 25: 579-586, 2001.
7. Klimstra DS and Longnecker DS: K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 145: 1547-1550, 1994.
8. Goggins M, Hruban RH and Kern SE: BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 156: 1767-1771, 2000.
9. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H and Shirai T: Genetic progression and divergence in pancreatic carcinoma. Am J Pathol 156: 2123-2133, 2000.
10. Morohoshi T, Kanda M, Asanuma K and Kloppel G: Intraductal papillary neoplasms of the pancreas. A clinicopathologic study of six patients. Cancer 64: 1329-1335, 1989.
11. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, Pellegata NS, Ranzani GN, Rickaert F and Kloppel G: Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchow Archiv 425: 357-367, 1994.
12. Loftus, Jr. EV, Olivares-Pakzad BA, Batts KP, Adkins MC, Stephens DH, Sarr MG and Dimagno EP: Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Gastroenterol 770: 1909-1918, 1996.
13. Longnecker DS, Adler G, Hruban RH and Kloppel G: Intraductal papillary-mucinous neoplasms of the pancreas. In: WHO Classification of Tumors of the Digestive System: pp. 237-240, 2000.
14. Yonezawa S, Horinouchi M, Osako M, Kubo M, Takao S, Arimura Y, Nagata K, Tanaka S, Sakoda, K, Aikou T and Sato E: Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol Int 49: 45-54, 1999.
15. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Saavedra JA, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, Goggins M, Kato Y, Kloppel G, Longnecher DS, Luttges J, Maitra A, Offerhaus GJA, Shimizu M and Yonezawa S: An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28: 977-987, 2004.
16. Biankin AV, Biankin SA, Kench JG, Morey AL, Lee C-S, Head DR, Eckstein RP, Hugh TB, Henshall SM and Sutherland RL: Aberrant p16INK4A and DPC4/Smad4 expression in intraductal papillary mucinous tumors of the pancreas is associated with invasive ductal carcinoma. Gut 50: 861-868, 2002.
17. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO and Goggins M: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 762: 1151-1162, 2003.
18. Guweidhi A, Kleeff J, Giese N, Fitori JE, Ketterer K, Giese T, Buchler MW, Korc M and Friess H: Enhanced expression of 14-3-3 sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis 25: 1575-1585, 2004.
19. Nakamura A, Horinouchi M, Goto M, Nagata K, Sakoda K, Takao S, Imai H, Kim YS, Sato E and Yonezawa S: New classification of pancreatic intraductal papillary-mucinous tumor by mucin expression: its relationship with potential for malignancy. J Pathol 797: 201-210, 2002.
20. Aitken A, Collinge DB, van Heusden BP, Isobe T, Roseboom PH, Rosenfeld G and Soll J: 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem Sci 17: 498-501, 1992.
21. Prasad GL, Valverius EM, McDuffie E and Cooper HL: Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 3: 507-513, 1992.
22. Leffers H, Madsen P, Rasmussen HH, Honore B, Andersen AH, Walbum E, Vandekerckhove J and Celis JE: Molecular cloning and expression of the transformation sensitive epithelial marker stratiffin. A member of a protein family that has been involved in the protein kinase C signaling pathway. J Mol Biol 231: 982-998, 1993.
23. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997.
24. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
25. Aprelikova O, Pace AJ, Fang B, Koller BH and Liu ET: BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. J Biol Chem 276: 25647-25650, 2001.
26. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y and Inoue S: Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417: 871-875, 2002.
27. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe V, Revillion F, Peyrat JP and Hondermarck H: Proteomic analysis reveals that 14-3-3 sigma is down-regulated in human breast cancer cells. Cancer Res 61: 76-80, 2001.
28. Moreira JM, Ohlsson G, Rank FE and Celis JE: Down-regulation of the tumor suppressor protein 14-3-3 sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics 4: 555-569, 2005.
29. Ide M, Nakajima T, Asao T and Kuwano H: Inactivation of 14-3-3 sigma by hypermethylation is a rare event in colorectal cancers and its expression may correlate with cell cycle maintenance at the invasion front. Cancer Lett 207: 241-249, 2004.
30. Nakajima T, Shimooka H, Weixa P, Segawa A, Motegi A, Jian Z, Masuda N, Ide M, Sano T, Oyama T, Tsukagoshi H, Hamanaka K and Maeda M: Immunohistochemical demonstration of 14-3-3 sigma protein in normal human tissues and lung cancers, and the preponderance of its strong expression in epithelial cells of squamous cell lineage. Pathol Int 53: 353-360, 2003.
31. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, Satoh T, Toyota J, Satoh M, Endo T and Imai K: Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19: 5298-5302, 2000.
32. Gasco M, Bell AK, Heath V, Sullivan A, Smith P, Hiller L, Yulug I, Numico G, Merlano M, Farrell PJ, Tavassoli M, Gusterson B and Crook T: Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res 62: 2072-2076, 2002.
33. Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, Dunne B, Gusterson B, Evans DJ and Crook T: Coincident inactivation of 14-3-3 sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene 21: 1876-1881, 2002.
34. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J and Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20: 3348-3353, 2001.
35. Adsay NV: Intraductal papillary mucinous neoplasms of the pancreas: pathology and molecular genetics. Gastrointest Surg 6: 656-659, 2002.
36. Terris B, Dubois S, Buisine MP, Sauvanet A, Ruszniewski P, Aubert JP, Porchet N, Couvelard A, Degott C and Flejou JF: Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. J Pathol 197: 632-637, 2002.
37. Yeh TS, Ho YP, Chiu CT, Chen TC, Jan YY and Chen MF: Aberrant expression of cdx2 homeobox gene in intraductal papillary-mucinous neoplasm of the pancreas but not in pancreatic ductal adenocarcinoma. Pancreas 30: 233-238, 2005.